Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies

被引：93
作者：
Lue L.-F. [1 ]
Guerra A. [1 ]
Walker D.G. [1 ]
机构：
[1] Banner-ASU Neurodegenerative Disease Research Center, Biodesign Institute, Arizona State University, Tempe, AZ
来源：
Neurology and Therapy | 2017年 / 6卷 / Suppl 1期
关键词：
Alzheimer’s disease; Amyloid beta; Blood biomarkers; Plasma; Tau; Ultra-sensitive technology;
D O I：
10.1007/s40120-017-0074-8
中图分类号：
学科分类号：
摘要：
The utility of the levels of amyloid beta (Aβ) peptide and tau in blood for diagnosis, drug development, and assessment of clinical trials for Alzheimer’s disease (AD) has not been established. The lack of availability of ultra-sensitive assays is one critical issue that has impeded progress. The levels of Aβ species and tau in plasma and serum are much lower than levels in cerebrospinal fluid. Furthermore, plasma or serum contain high levels of assay-interfering factors, resulting in difficulties in the commonly used singulex or multiplex ELISA platforms. In this review, we focus on two modern immune-complex-based technologies that show promise to advance this field. These innovative technologies are immunomagnetic reduction technology and single molecule array technology. We describe the technologies and discuss the published studies using these technologies. Currently, the potential of utilizing these technologies to advance Aβ and tau as blood-based biomarkers for AD requires further validation using already collected large sets of samples, as well as new cohorts and population-based longitudinal studies. © 2017, The Author(s).
引用
收藏
页码：25 / 36
页数：11
相关论文
共 74 条
[1]  
Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Matsushita S., Machida N., Nakagawa T., Lee V.M., Trojanowski J.Q., Sasaki H., Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer’s disease, J Am Geriatr Soc, 45, pp. 1228-1231, (1997)
[2]  
Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss M.A., Seubert P., High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype, Arch Neurol, 55, pp. 937-945, (1998)
[3]  
Lasser R.A., Dukoff R., Levy J., Levin R., Lehtimaki T., Seubert P., Sunderland T., Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer’s disease, Int J Geriatr Psychiatry, 13, pp. 767-774, (1998)
[4]  
Pirttila T., Mehta P.D., Soininen H., Kim K.S., Heinonen O., Paljarvi L., Kosunen O., Riekkinen P., Wisniewski H.M., Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer’s disease: correlations with amyloid load in the brain, Arch Neurol, 53, pp. 189-193, (1996)
[5]  
Tabaton M., Nunzi M.G., Xue R., Usiak M., Autilio-Gambetti L., Gambetti P., Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid, Biochem Biophys Res Commun, 200, pp. 1598-1603, (1994)
[6]  
Okamura N., Harada R., Furukawa K., Furumoto S., Tago T., Yanai K., Arai H., Kudo Y., Advances in the development of tau PET radiotracers and their clinical applications, Ageing Res Rev, 30, pp. 107-113, (2016)
[7]  
Heurling K., Leuzy A., Zimmer E.R., Lubberink M., Nordberg A., Imaging beta-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis, Eur J Nucl Med Mol Imaging, 43, pp. 362-373, (2016)
[8]  
Blennow K., Zetterberg H., The past and the future of Alzheimer’s disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events, Front Neurosci, 9, (2015)
[9]  
Molinuevo J.L., Blennow K., Dubois B., Engelborghs S., Lewczuk P., Perret-Liaudet A., Teunissen C.E., Parnetti L., The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative, Alzheimers Dement, 10, pp. 808-817, (2014)
[10]  
Trojanowski J.Q., Vandeerstichele H., Korecka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W.Z., Weiner M.W., Jack C.R., Jagust W., Toga A.W., Lee V.M., Shaw L.M., Update on the biomarker core of the Alzheimer’s Disease neuroimaging initiative subjects, Alzheimers Dement, 6, pp. 230-238, (2010)
12345678